|02/16/17||Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx|
|- Ionis and Akcea to receive $75 million up-front payment
- Deal valued at more than $1 billion
CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today they have closed on their exclusive, worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx following clearance unde... |
|02/15/17||Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call|
|Webcast scheduled for Tuesday, February 28 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., Feb. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 28 at 11:30 a.m. Eastern Time to discuss its 2016 financial results and report on pipeline and business progress.
Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A ... |
|02/14/17||Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx|
|CARLSBAD, Calif., Feb. 14, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the advancement of IONIS-FXIRx in clinical development under an existing exclusive license agreement with Bayer. Under this agreement, Ionis will also initiate development of IONIS-FXI-LRx, which uses Ionis' proprietary LIgand Conjugated Antisense, or LICA, technology. In conjunction with the decision to advance these programs, Ionis will receive a $75 million payment from Bayer.
|02/02/17||Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration|
|CARLSBAD, Calif., Feb. 2, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.
|02/01/17||Ionis Pharmaceuticals to Present at Upcoming Investor Conferences|
|CARLSBAD, Calif., Feb. 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 in New York, NY; and
Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 in Boston, MA.
The above listed ... |
|01/13/17||New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy|
|Primary Endpoint from End of Study Analysis Presented at British Paediatric Neurology Association Annual Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. The data were prese... |
|01/06/17||Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance|
|Strong financial performance resulting from the continued success of pipeline programs
CARLSBAD, Calif., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Company expects to significantly improve upon its 2016 financial guidance. Ionis expects to end 2016 with pro forma net operating income in the low to mid $20 million range and more than $650 million in cash. The Company's significantly improved financial guidance is the result of numerous ac... |
|01/06/17||Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx|
|- Collaboration with Novartis provides near-term payments of $225 million plus potential license fees, milestone and royalty payments
- Akcea retains rights to co-commercialize to lipid specialists
- Deal valued at significantly over $1 billion if both drugs are licensed and successfully commercialized
- Company to host conference call at 9:30 a.m. Eastern Time
CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals Inc. (NASDAQ: IONS) and Akcea Ther... |
|01/04/17||Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes|
|- Company to present top-line results at Pipeline Update Webcast on January 5 -
CARLSBAD, Calif., Jan. 4, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes. In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGRRx achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c) and ... |